Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
Sell
-11,000
Closed -$241K 294
2016
Q4
$241K Sell
11,000
-9,000
-45% -$2.67M 0.28% 71
2016
Q3
$149K Sell
20,000
-5,000
-20% -$1.48M 0.12% 124
2016
Q2
$1.07M Buy
25,000
+10,000
+67% +$2.64M 0.92% 23
2016
Q1
$605K Buy
15,000
+3,500
+30% +$925K 0.63% 31
2015
Q4
$297K Buy
+11,500
New +$3.3M 0.22% 78

Other funds holding BIIB

FT Options's BIIB Position: Q1 2017 in Review

FT Options sold out of Biogen (BIIB) in Q1 2017, closing a stake of 3,191 shares — an estimated $905K sold.

FT Options first reported a position in BIIB in Q4 2015 and held it in 4 quarters. The position peaked at $3.54M in Q2 2016. 1,019 funds tracked by Wall St. Rank hold BIIB as of Q1 2017.

  • FT Options reported no remaining Biogen position as of Q1 2017 after selling out during the quarter.
  • FT Options sold 3,191 Biogen shares in Q1 2017, an estimated $905K.
  • FT Options first reported a position in Biogen in Q4 2015 and held it in 4 quarters.
  • FT Options's Biogen position peaked at $3.54M in Q2 2016.
  • 1,019 funds tracked by Wall St. Rank held Biogen as of Q1 2017.

Based on FT Options's 13F filing for Q1 2017, filed 12 May 2017.